TABLE II.
Resource use and costs of blood product administration
| Blood product | Unit cost (2012 CA$) | Source |
Mean units of blood product per cycle8 by myelodysplastic syndrome treatment arm
|
|||
|---|---|---|---|---|---|---|
| aza | bsc | ldc | sdc | |||
| Packed red cells (mean for all times) | 338.77 | Amin et al.10 | 1.42 | 2.56 | 2.65 | 3.99 |
| 0–6 Months | 2.04 | 2.59 | 2.84 | 3.99 | ||
| 7–12 Months | 0.95 | 2.32 | 1.49 | na | ||
| ≥ 13 Months | 0.58 | 2.13 | 0.97 | na | ||
| Platelets (mean for all times) | 570.98 | mohltc11 | 1.12 | 0.63 | 1.87 | 4.63 |
| 0–6 Months | 1.83 | 0.81 | 2.09 | 4.63 | ||
| 7–12 Months | 0.46 | 0.30 | 1.30 | na | ||
| ≥ 13 Months | 0.13 | 0.29 | 0.45 | na | ||
|
| ||||||
| Mean cost of blood products per cycle (2012 CA$) | 1,120.56 | 1,226.97 | 1,965.48 | 3,995.34 | ||
aza = azacitidine; bsc = best supportive care; ldc = low-dose chemotherapy; sdc = standard-dose chemotherapy; na = not available; mohltc = (Ontario) Ministry of Health and Long-Term Care.